Hyperhomocysteinemia: A new risk factor for degenerative diseases

Clinical Laboratory

Volumn 48, Issue 9-10, 2002, Pages 471-481

  Herrmann, Wolfgang ^a   Knapp, Jean Pierre ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Age; B vitamins; Homocysteine; Hyperhomocysteinemia; Metabolism; Vegetarians

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; HYDROXOCOBALAMIN; METHIONINE; METHYLMALONIC ACID; PYRIDOXINE; TRANSCOBALAMIN II;

AGED; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG ABSORPTION; EARLY DIAGNOSIS; ENZYME DEFICIENCY; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; KIDNEY DISEASE; NEURAL TUBE DEFECT; OBESITY; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTMENOPAUSE; PREECLAMPSIA; PREGNANCY DISORDER; PREVALENCE; RELIABILITY; REVIEW; RISK FACTOR; STROKE; VEGETARIAN DIET; VEIN THROMBOSIS; VITAMIN BLOOD LEVEL;

BRAIN DISEASES; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; PREGNANCY; RISK FACTORS; VASCULAR DISEASES; VITAMIN B 12 DEFICIENCY;

EID: 0036398629     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Knekt P, Reunanen A, Alfthan G et al. Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 2001;161:1589-94.
2. Cavalca V, Cighetti G, Bamonti F et al. Oxidative stress and homocysteine in coronary artery disease. Clin Chem 2001;47: 887-92.
3. Genest JJ, Jr., McNamara JR, Upson B et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991;11:1129-36.
4. Anderson JL, Muhlestein JB, Horne BD et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-32.
5. Abdelmouttaleb I, Danchin N, Aimone-Gastin I et al. Homocysteine, vitamins B6, B12, folate, and risk of coronary artery disease in patients undergoing diagnostic coronary angiography. Amino Acids 2000;18:139-46.
6. Pinto X, Vilaseca MA, Garcia-Giralt N et al. Homocysteine and the MTHFR 677C→T allele in premature coronary artery disease. Case control and family studies. Eur J Clin Invest 2001;31: 24-30.
7. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001;158:425-30.
8. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000;31:1069-75.
9. Andersson A, Hutlberg B, Lindgren A. Redox status of plasma homocysteine and other plasma thiols in stroke patients. Atherosclerosis 2000;151:535-9.
10. Shimizu H, Kiyohara Y, Kato I et al. Plasma homocyst(e)ine concentrations and the risk of subtypes of cerebral infarction. The Hisayama study. Cerebrovasc Dis 2002;13:9-15.
11. Boers GH, Smals AG, Trijbels FJ et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
12. Malinow MR, Kang SS, Taylor LM et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-8.
13. Brattstrom L, Israelsson B, Norrving B et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
14. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-98.
15. de Jong S. Hyperhomocysteinaemia in patients with peripheral arterial occlusive disease. Clin Chem Lab Med 2001;39:714-6.
16. Loehrer FM, Tschopl M, Angst CP et al. Disturbed ratio of erythrocyte and plasma S-adenosylmethionine/S- adenosylhomocysteine in peripheral arterial occlusive disease. Atherosclerosis 2001;154:147-54.
17. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995;15:1321-3.
18. den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
19. Simioni P, Prandoni P, Burlina A et al. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost 1996;76:883-6.
20. Cattaneo M, Martinelli I, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 335:974-5.
21. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
22. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci USA 1996;93:15227-32.
23. Mills JL, Scott JM, Kirke PN et al. Homocysteine and neural tube defects. J Nutr 1996;126:756S-60S.
24. Eskes TK. Neural tube defects, vitamins and homocysteine. Eur J Pediatr 1998;157 Suppl 2:S139-S141.
25. Afman LA, Van Der Put NM, Thomas CM, Trijbels JM, Blom HJ. Reduced vitamin B12 binding by transcobalamin II increases the risk of neural tube defects. QJM 2001;94:159-66.
26. Nelen WL, Steegers EA, Eskes TK, Blom HJ. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997;350:861.
27. Vollset SE, Refsum H, Irgens LM et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study. Am J Clin Nutr 2000;71:962-8.
28. Nilsson K, Gustafson L, Faldt R et al. Hyperhomocysteinaemia-a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-9.
29. Nilsson K, Gustafson L, Hultberg B. Relation between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:7-12.
30. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
31. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-13.
32. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002;58:1539-41.
33. 6 occur commonly in elderly people. Am J Clin Nutr 1993;58: 468-76.
34. 12 deficiency in the elderly: current dilemmas. Am J Clin Nutr 1997;66:741-9.
35. 12 and folate tissue deficiency markers amongst elderly Swedes- -a population-based study. J Intern Med 2001;249:423-32.
36. Carmel R, Green R, Jacobsen DW, Rasmussen K, Florea M, Azen C. Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr 1999;70:904-10.
37. van Guldener C, Stehouwer CD. Homocysteine-lowering treatment: an overview. Expert Opin Pharmacother 2001;2:1449-60.
38. Tice JA, Ross E, Coxson PG et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 2001;286:936-43.
39. Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS. Potential clinical and economic effects of homocyst(e)ine lowering. Arch Intern Med 2000;160:3406-12.
40. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19: 217-46.
41. Chiang PK, Gordon RK, Tal J et al. S-Adenosylmethionine and methylation. FASEB J 1996;10:471-80.
42. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Baudet AL, Sly WS, eds. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 1995: 1279-327.
43. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetra-hydrofolate reductase [letter]. Nat Genet 1995;10: 111-3.
44. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996;19:171-8.
45. 6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
46. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495-502.
47. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181-9.
48. Herrmann W, Quast S, Ellgass A et al. An increased serum level of free Apo(a) in renal patients is more striking than that of Lp(a) and is influenced by homocysteine. Nephron 2000;85:41-9.
49. Herrmann W, Schorr H, Geisel J, Riegel W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin Chem Lab Med 2001;39:739-46.
50. van der Griend R, Haas FJ, Biesma DH, Duran M, Meuwissen OJ, Banga JD. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives. Atherosclerosis 1999;143:177-83.
51. Montalescot G. Homocysteine: the new player in the field of coronary risk. Heart 1996;76:101-2.
52. 12, and total antioxidant status in vegetarians. Clin Chem 2001;47:1094-101.
53. Ulleland M, Eilertsen I, Quadros EV et al. Direct assay for cobalamin bound to transcobalamin (holo- transcobalamin) in serum. Clin Chem 2002;48:526-32.
54. Carmel R. Measuring and interpreting holo-transcobalamin (holo-transcobalamin II). Clin Chem 2002;48:407-9.
55. Herrmann W, Schorr H, Bodis M et al. Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects. Eur J Clin Invest 2000;30:1083-9.
56. Lindgren A, Kilander A, Bagge E, Nexo E. Holotranscobalamin - a sensitive marker of cobalamin malabsorption. Eur J Clin Invest 1999;29:321-9.
57. 12 (cobalamin) status in vegetarians. Am J Clin Nutr 1994;59:1213S-22S.
58. 12 status of long-term adherents of a strict uncooked vegan diet ("living food diet") is compromised. J Nutr 1995;125:2511-5.
59. 12 status on a mostly raw vegan diet with follow-up using tablets, nutritional yeast, or probiotic supplements. Ann Nutr Metab 2000;44:229-34.
60. 12 status. Clin Chim Acta, in press 2002.
61. Herrmann W, Schorr H, Obeid R, Geisel J., submitted 2002.
62. Markle HV. Cobalamin. Crit Rev Clin Lab Sci 1996;33:247-356.
63. Herrmann W, Quast S, Ullrich M, Schultze H, Bodis M, Geisel J. Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis 1999;144:91-101.
64. Nygard O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-33.
65. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies [see comments]. Am J Med 1994;96:239-46.
66. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population [see comments]. JAMA 1993;270: 2693-8.
67. Bates CJ, Pentieva KD, Prentice A, Mansoor MA, Finch S. Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over. Br J Nutr 1999;81: 191-201.
68. van den Berg M, de Jong SC, Deville W et al. Variability of fasting and post-methionine plasma homocysteine levels in normo- and hyperhomocysteinaemic individuals. Neth J Med 1999;55:29-38.
69. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71:614S-20S.
70. Nilsson K, Gustafson L, Faldt R et al. Hyperhomocysteinaemia-a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-9.
71. Gottfries CG, Lehmann W, Regland B. Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease. J Neural Transm 1998;105:773-86.
72. Leblhuber F, Walli J, Artner-Dworzak E et al. Hyperhomocysteinemia in dementia. J Neural Transm 2000;107:1469-74.
73. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-55.
74. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-9.
75. Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for atherosclerosis. Ann Pharmacother 2000;34:57-65.
76. (12) and folate in relation to the development of Alzheimer's disease. Neurology 2001;56:1188-94.
77. Nilsson K, Gustafson L, Hultberg B. The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. Clin Chem 2000;46:691-6.
78. 12 deficiency. Arch Intern Med 2001;161:1534-41.
79. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition 2000;16:544-6.
80. 12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry 1990;53:951-4.
81. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine is a sensitive marker for tissue deficiency of both cobalamines and folates in a psychogeriatric population. Dement Geriatr Cogn Disord 1999;10:476-82.
82. Serot JM, Christmann D, Dubost T, Bene MC, Faure GC. CSF-folate levels are decreased in late-onset AD patients. J Neural Transm 2001;108:93-9.
83. El Kossi MM, Zakhary MM. Oxidative stress in the context of acute cerebrovascular stroke. Stroke 2000;31:1889-92.
84. Bolander-Gouaille C. Focus on Homocysteine. Springer-Verlag France, 2002:52-62pp.
85. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-9S.
86. 12 and folate. Br Med Bull 1999;55:669-82.
87. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 1996;67:1328-31.
88. Fekkes D, van der Cammen TJ, van Loon CP et al. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J Neural Transm 1998;105:287-94.
89. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression 5. J Neurol Neurosurg Psychiatry 2000;69:228-32.
90. Bottiglieri T, Hyland K, Laundy M et al. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med 1992;22:871-6.
91. Surtees R, Heales S, Bowron A. Association of cerebrospinal fluid deficiency of 5- methyltetrahydrofolate, but not S-adenosylmethionine, with reduced concentrations of the acid metabolites of 5-hydroxytryptamine and dopamine. Clin Sci (Lond) 1994;86:697-702.
92. Villalobos MA, De La Cruz JP, Cuerda MA, Ortiz P, Smith-Agreda JM, Sanchez DLC. Effect of S-adenosyl-L-methionine on rat brain oxidative stress damage in a combined model of permanent focal ischemia and global ischemia- reperfusion. Brain Res 2000;883:31-40.
93. Kingston AE, Lowndes J, Evans N et al. Sulphur-containing amino acids are agonists for group 1 metabotropic receptors expressed in clonal RGT cell lines. Neuropharmacology 1998;37: 277-87.
94. Bolander-Gouaille C. Focus on Homocysteine. Springer-Verlag France, 2002:121-123pp.
95. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
96. Malinow MR, Ducimetiere P, Luc G et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996;126:27-34.
97. Peterson JC, Spence DJ. Vitamins and progression of atherosclerosis in hyper-homocysteinaemia. Lancet 1998;351:263
98. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345 :1593-600.
99. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease [published erratum appears in Circulation 1998 Feb 24;97(7):711]. Circulation 1998;97:138-41.
100. Suliman ME, Qureshi AR, Barany P et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57:1727-35.
101. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.
102. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999;55:315-20.
103. Moelby L, Rasmussen K, Ring T, Nielsen G. Relationship between methylmalonic acid and cobalamin in uremia. Kidney Int 2000;57:265-73.
104. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism 1999;48:631-5.
105. Arnadottir M, Gudnason V, Hultberg B. Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 2000;15:524-8.
106. Sunder-Plassmann G, Fodinger M, Buchmayer H et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000;11:1106-16.
107. Bostom AG, Shemin D, Bagley P et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000;101:2829-32.
108. Elian KM, Hoffer LJ. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism 2002;51: 881-6.
109. 12. Eur J Clin Nutr 1997;51 Suppl 1:S49-S53.
110. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int 2001;59 Suppl 78:S234-S237.
111. Hebert LA. Renoprotective therapy: how good can it get? Kidney Int 2000;57:343-4.
112. Nelen WL. Hyperhomocysteinaemia and human reproduction. Clin Chem Lab Med 2001;39:758-63.
113. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Thomas CM, Eskes TK. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. Obstet Gynecol 2000;95:519-24.
114. Nelen WL, Bulten J, Steegers EA, Blom HJ, Hanselaar AG, Eskes TK. Maternal homocysteine and chorionic vascularization in recurrent early pregnancy loss. Hum Reprod 2000;15:954-60.
115. Steegers-Theunissen RP, Boers GH, Trijbels FJ, Eskes TK. Neural-tube defects and derangement of homocysteine metabolism. N Engl J Med 1991;324:199-200.
116. Steegers-Theunissen RP, Boers GH, Trijbels FJ et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994;43:1475-80.
117. Powers RW, Evans RW, Majors AK et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998;179:1605-11.
118. Kark JD, Selhub J, Adler B, Gofin J, Abramson JH, Friedman G, Rosenberg IH. Nonfasting plasma total homocystein level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 1999;131:321-30.